XENBEXUS Trademark

Trademark Overview

On Tuesday, February 18, 2020, a trademark application was filed for XENBEXUS with the United States Patent and Trademark Office. The USPTO has given the XENBEXUS trademark a serial number of 88801374. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 2, 2024. This trademark is owned by Celgene Corporation. The XENBEXUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, antifungal preparations, antivirals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer and cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy and T Cell ther...
xenbexus

General Information

Serial Number88801374
Word MarkXENBEXUS
Filing DateTuesday, February 18, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 1, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, antifungal preparations, antivirals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer and cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy and T Cell therapy use; Pharmaceutical preparations for human use, namely, stem cells for medical and medical clinic purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, February 22, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Friday, February 21, 2020NEW APPLICATION ENTERED
Sunday, March 29, 2020ASSIGNED TO EXAMINER
Monday, September 28, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, February 22, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 30, 2020NON-FINAL ACTION WRITTEN
Monday, March 30, 2020NON-FINAL ACTION E-MAILED
Monday, March 30, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, September 28, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 29, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 23, 2020FINAL REFUSAL WRITTEN
Friday, October 23, 2020FINAL REFUSAL E-MAILED
Friday, October 23, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, April 23, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, April 23, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, April 24, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 26, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 12, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 1, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 1, 2021PUBLISHED FOR OPPOSITION
Wednesday, January 19, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 27, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 24, 2023SOU EXTENSION 3 GRANTED
Wednesday, January 19, 2022SOU EXTENSION 1 FILED
Wednesday, January 19, 2022SOU EXTENSION 1 GRANTED
Friday, January 21, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 13, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 13, 2022SOU EXTENSION 2 FILED
Wednesday, July 13, 2022SOU EXTENSION 2 GRANTED
Friday, July 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 24, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, January 24, 2023SOU EXTENSION 3 FILED
Thursday, July 13, 2023SOU EXTENSION 4 FILED
Thursday, July 13, 2023SOU EXTENSION 4 GRANTED
Friday, January 19, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, January 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 13, 2023SOU TEAS EXTENSION RECEIVED
Saturday, July 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 3, 2024SOU EXTENSION 5 FILED
Friday, January 19, 2024SOU EXTENSION 5 GRANTED
Saturday, January 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

xenbexus diseases pharmaceutical preparations human immune disorders system cancer treatment multiple